Mirum Pharma Highlights Presentation Of Analyses From Its Rare Liver Disease Programs At EASL Int’l. Liver Congress
- Data from five years of treatment with maralixibat reinforces safety and tolerability in patients with Alagille syndrome.
- Intrahepatic cholestasis of pregnancy patient-reported data demonstrates significant burden
Y-mAbs Provides Regulatory Update On Omburtamab For Treatment Of Patients With Neuroblastoma; Co’s President Says ‘Moving The Timeline Into The Fourth Quarter’ For Resubmission Of Omburtamab BLA
Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic
DURECT Highlights Presentation Of Added Clinical Data From DUR-928 Phase 1b Trial In NASH, Phase 1 Trial In Hepatic Impairment At Int’l. Liver Conference Jun. 23-26
DURECT Corporation (NASDAQ:DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic steatohepatitis (NASH) and a Phase 1 trial in subjects with hepatic
Medicenna Announces Submission Of Clinical Trial Application In Australia For Phase 1/2 Study Of MDNA11
Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that it has submitted a clinical trial application to a
Gilead’s Kite Says Gains First CAR T-Cell Therapy Approval In China
Kite, a Gilead Company, announced that Fosun Kite Biotechnology Co., Ltd., a joint venture between Kite and Shanghai Fosun Pharmaceutical (Group) Co., Ltd, has received approval from the China National Medical Products
SCYNEXIS Reports Will Launch Update For BREXAFEMME; To Host Call Tuesday, Jun. 29 At 12 p.m. EDT
BREXAFEMME, a one-day, novel, oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp antifungal development pipeline and the first approved drug from a novel antifungal
Chemomab Therapeutics reports Expanded Partnership With AGC Biologics To Manufacture CM-101 For Phase 2/3
AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facility
TEL AVIV, Israel and SEATTLE, June 23, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB), a clinical-stage
Entera Bio Reports Topline Phase 2 Bone Mineral Density Data For EB613, Study Met Primary Endpoint
Subjects receiving the 2.5 mg dose of EB613 showed significant dose-related increases in BMD at the lumbar spine, total hip, and femoral neck at 6 months
Subjects receiving the 2.5 mg dose of EB613 for 6 months had a